Senti Biosciences Inc (SNTI)

$2.08 +0.08 (4.00%)
Market Cap 52.32M
Revenue (ttm) 0.00
Net Income (ttm) -52.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 117,700
Avg Vol 203,944
Day's Range N/A - N/A
Shares Out 26.16M
Stochastic %K 44%
Beta 2.04
Analysts Strong Sell
Price Target $12.00

Company Profile

Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company's product candidates also include SENTI-202, a logic gated off-the-shelf...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 239 2030
Address:
2 Corporate Drive, First Floor, South San Francisco, United States
winners18
winners18 Oct. 25 at 5:16 PM
$SNTI mentioned potential BTD from last presentation
0 · Reply
Kingcrab3333
Kingcrab3333 Oct. 24 at 5:13 PM
$SNTI
0 · Reply
Lexxy86
Lexxy86 Oct. 24 at 2:38 PM
$SNTI Dropping data soon. Easy $12
0 · Reply
winners18
winners18 Oct. 24 at 3:58 AM
$SNTI 20 pts data will be presented at ash. If data continue to impress, sky is the limit.
0 · Reply
winners18
winners18 Oct. 24 at 3:56 AM
$SNTI https://www.fiercebiotech.com/biotech/ipsen-writes-check-worth-eu1b-acquire-next-gen-cancer-biotech
0 · Reply
winners18
winners18 Oct. 24 at 3:52 AM
$SNTI https://www.targetedonc.com/view/ict01-boosts-aml-remission-and-survival-in-eviction-trial
0 · Reply
Lexxy86
Lexxy86 Oct. 23 at 12:54 AM
$SNTI only a matter of time here
0 · Reply
Moneymike314
Moneymike314 Oct. 22 at 2:41 PM
$SNTI excited yet patiently waiting for this to be 2.75+ and reading all the comments from fomo and the like
0 · Reply
AnaDiggs836
AnaDiggs836 Oct. 21 at 4:50 PM
$SNTI developing biotech recovery; AITX recovering markets through AI precision — confirmed profitability and efficiency gains.
0 · Reply
WendyBolek286
WendyBolek286 Oct. 21 at 4:47 PM
$SNTI developing biotech recovery; AITX recovering markets through AI precision — confirmed profitability and efficiency gains.
0 · Reply
Latest News on SNTI
Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference

Oct 16, 2025, 9:05 AM EDT - 9 days ago

Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference

Senti Bio to Present at BioJapan

Oct 6, 2025, 9:05 AM EDT - 19 days ago

Senti Bio to Present at BioJapan

Senti Bio to Present at the MedInvest Biotech & Pharma Conference

Sep 18, 2025, 9:15 AM EDT - 5 weeks ago

Senti Bio to Present at the MedInvest Biotech & Pharma Conference

Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 9:05 AM EDT - 7 weeks ago

Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 9:15 AM EDT - 2 months ago

Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

Aug 12, 2025, 9:15 AM EDT - 2 months ago

Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

Aug 7, 2025, 8:05 AM EDT - 2 months ago

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia

Aug 5, 2025, 8:30 AM EDT - 2 months ago

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia

Senti Biosciences Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 3 months ago

Senti Biosciences Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum

Jul 21, 2025, 8:55 AM EDT - 3 months ago

Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum

Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors

Jul 18, 2025, 8:55 AM EDT - 3 months ago

Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors

Senti Bio Participates in Nasdaq Amplify Spotlight Series

Jun 30, 2025, 9:15 AM EDT - 4 months ago

Senti Bio Participates in Nasdaq Amplify Spotlight Series

Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference

Jun 24, 2025, 8:45 AM EDT - 4 months ago

Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference

Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia

Jun 18, 2025, 7:00 AM EDT - 4 months ago

Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia

Senti Biosciences Announces New Employment Inducement Grants

Jun 9, 2025, 4:30 PM EDT - 4 months ago

Senti Biosciences Announces New Employment Inducement Grants

Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC

Jun 6, 2025, 9:05 AM EDT - 5 months ago

Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Shareholders to Inquire about Securities Investigation

May 30, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Connect

May 29, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Reach Out

May 28, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Shareholders to Learn More About the Investigation

May 27, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Investors to Learn More About the Investigation

May 26, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Investors to Learn More About the Investigation

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 25, 2025, 10:00 AM EDT - 5 months ago

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Investors to Connect

May 23, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Investors to Connect

Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 22, 2025, 4:05 PM EDT - 5 months ago

Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Stockholders to Inquire about Securities Investigation

May 22, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Stockholders to Inquire about Securities Investigation

Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202

May 22, 2025, 8:30 AM EDT - 5 months ago

Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Investors to Inquire about Securities Investigation

May 21, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Investors to Reach Out

May 20, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Investors to Reach Out

SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm

May 20, 2025, 5:28 AM EDT - 5 months ago

SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Stockholders to Reach Out

May 19, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Stockholders to Connect

May 18, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Stockholders to Connect

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 16, 2025, 2:00 PM EDT - 5 months ago

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202

May 8, 2025, 8:35 AM EDT - 6 months ago

Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202

Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development

May 6, 2025, 4:35 PM EDT - 6 months ago

Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development

Senti Bio Releases Virtual Investor “What This Means” Segment

May 1, 2025, 9:15 AM EDT - 6 months ago

Senti Bio Releases Virtual Investor “What This Means” Segment

Senti Bio to Present at the Citizens JMP Life Sciences Conference

Apr 30, 2025, 9:00 AM EDT - 6 months ago

Senti Bio to Present at the Citizens JMP Life Sciences Conference

Senti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML

Apr 28, 2025, 7:00 AM EDT - 6 months ago

Senti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML

Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8:30 AM ET

Apr 24, 2025, 8:35 AM EDT - 6 months ago

Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8:30 AM ET

Senti Bio Participates in a Virtual Investor KOL Connect Segment

Apr 21, 2025, 9:05 AM EDT - 6 months ago

Senti Bio Participates in a Virtual Investor KOL Connect Segment

winners18
winners18 Oct. 25 at 5:16 PM
$SNTI mentioned potential BTD from last presentation
0 · Reply
Kingcrab3333
Kingcrab3333 Oct. 24 at 5:13 PM
$SNTI
0 · Reply
Lexxy86
Lexxy86 Oct. 24 at 2:38 PM
$SNTI Dropping data soon. Easy $12
0 · Reply
winners18
winners18 Oct. 24 at 3:58 AM
$SNTI 20 pts data will be presented at ash. If data continue to impress, sky is the limit.
0 · Reply
winners18
winners18 Oct. 24 at 3:56 AM
$SNTI https://www.fiercebiotech.com/biotech/ipsen-writes-check-worth-eu1b-acquire-next-gen-cancer-biotech
0 · Reply
winners18
winners18 Oct. 24 at 3:52 AM
$SNTI https://www.targetedonc.com/view/ict01-boosts-aml-remission-and-survival-in-eviction-trial
0 · Reply
Lexxy86
Lexxy86 Oct. 23 at 12:54 AM
$SNTI only a matter of time here
0 · Reply
Moneymike314
Moneymike314 Oct. 22 at 2:41 PM
$SNTI excited yet patiently waiting for this to be 2.75+ and reading all the comments from fomo and the like
0 · Reply
AnaDiggs836
AnaDiggs836 Oct. 21 at 4:50 PM
$SNTI developing biotech recovery; AITX recovering markets through AI precision — confirmed profitability and efficiency gains.
0 · Reply
WendyBolek286
WendyBolek286 Oct. 21 at 4:47 PM
$SNTI developing biotech recovery; AITX recovering markets through AI precision — confirmed profitability and efficiency gains.
0 · Reply
Kingcrab3333
Kingcrab3333 Oct. 21 at 5:28 AM
$SNTI
0 · Reply
IndiraSolano436
IndiraSolano436 Oct. 20 at 4:16 PM
$SNTI researching recovery, AITX recovering faster — profitability achieved, revenue up nearly 50%, and cost controls stronger than ever.
0 · Reply
Sw1ngb0t
Sw1ngb0t Oct. 16 at 2:06 PM
$SNTI got it
0 · Reply
SCV89
SCV89 Oct. 16 at 1:47 PM
$SNTI 👀
0 · Reply
TheGhostOfEd
TheGhostOfEd Oct. 16 at 2:46 AM
$SNTI Great rebound today.....looking for 4-5+ by end of year
0 · Reply
SCV89
SCV89 Oct. 15 at 7:37 PM
$SNTI added to 14500 shares at 2.20 let’s gooooo
0 · Reply
SCV89
SCV89 Oct. 15 at 3:18 PM
$SNTI loaded loaded loaded 13000 shares at $2.20 this is looking to explode with higher PT and news incoming
0 · Reply
Lexxy86
Lexxy86 Oct. 15 at 2:22 PM
$SNTI know what you hold 💎💎💎
0 · Reply
Lexxy86
Lexxy86 Oct. 15 at 2:20 PM
$SNTI interim data took this from $2 to $10 in one day. Can’t wait for the complete data release
0 · Reply
dbr_island
dbr_island Oct. 15 at 1:45 PM
$NUAI 🚨LIFE CHANGED🚨 $GURE will be $1+ I tell you imo Stop ignoring smart money!!!! $SNTI $STI $SDOT lets get it
0 · Reply
ripriprip
ripriprip Oct. 15 at 3:18 AM
$SNTI I am excited about their data that could be released at any time. Could be a game changer. However, this is a boom or bust play. By Dec 31, SP is either $10-15 or pennies.
0 · Reply
Lexxy86
Lexxy86 Oct. 15 at 12:09 AM
$SNTI Incredibly small float. A bargain price currently. Enormous potential and trending upwards from here on
0 · Reply